An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

[1]  Ellery Wulczyn,et al.  Deep learning-based survival prediction for multiple cancer types using histopathology images , 2019, PloS one.

[2]  Peter W. Laird,et al.  Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas , 2017, JAMA oncology.

[3]  A. Services,et al.  Integrated genomic and molecular characterization of cervical cancer. , 2017 .

[4]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[5]  Steven J. M. Jones,et al.  Integrated genomic and molecular characterization of cervical cancer , 2017, Nature.

[6]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[7]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[8]  K. Ross,et al.  Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[10]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[11]  Sean Khozin,et al.  Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Xianglin L. Du,et al.  Crossover Effects of Estrogen Receptor Status on Breast Cancer-Specific Hazard Rates by Age and Race , 2014, PloS one.

[13]  Benjamin J. Raphael,et al.  Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.

[14]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[15]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[16]  A. Giobbie-Hurder,et al.  Challenges of guarantee-time bias. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[18]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[19]  L. Schwartz,et al.  When progressive disease does not mean treatment failure: reconsidering the criteria for progression. , 2012, Journal of the National Cancer Institute.

[20]  Keda Yu,et al.  Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy. , 2012, The Journal of clinical endocrinology and metabolism.

[21]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[22]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[23]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[24]  Daniel J Sargent,et al.  Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[26]  D. Moher,et al.  CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials , 2010, Journal of pharmacology & pharmacotherapeutics.

[27]  G. Salles,et al.  Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[29]  D. Sargent,et al.  Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials , 2009, International Journal of Clinical Oncology.

[30]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[31]  James R. Anderson,et al.  Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Labianca,et al.  Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. , 2007, Journal of the National Cancer Institute.

[33]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[35]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[36]  G. Vlastos,et al.  Minimum follow-up time required for the estimation of statistical cure of cancer patients: verification using data from 42 cancer sites in the SEER database , 2005, BMC Cancer.

[37]  S. Schnitt.  Risk factors for local recurrence in patients with invasive breast cancer and negative surgical margins of excision. Where are we and where are we going? , 2003, American journal of clinical pathology.

[38]  T G Clark,et al.  Survival Analysis Part I: Basic concepts and first analyses , 2003, British Journal of Cancer.

[39]  Richard Pazdur,et al.  End points and United States Food and Drug Administration approval of oncology drugs. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Shen.  Testing for sufficient follow-up in survival data , 2000 .

[41]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[42]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[43]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[44]  J. Concato,et al.  A simulation study of the number of events per variable in logistic regression analysis. , 1996, Journal of clinical epidemiology.

[45]  R. Gray,et al.  Annual hazard rates of recurrence for breast cancer after primary therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Concato,et al.  Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. , 1995, Journal of clinical epidemiology.

[47]  Ross Maller,et al.  Testing for Sufficient Follow-Up and Outliers in Survival Data , 1994 .

[48]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[49]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  H. Rubash.  MASSACHUSETTS General Hospital. , 1957, Medical times.